Dermata Therapeutics
DRMA
8 hedge funds and large institutions have $226K invested in Dermata Therapeutics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
33% more funds holding
Funds holding: 6 → 8 (+2)
0% less ownership
Funds ownership: 0% → 0% (-0%)
81% less capital invested
Capital invested by funds: $1.19M → $226K (-$960K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$141K |
| 2 |
Two Sigma Investments
New York
|
+$70.7K |
| 3 |
JP Morgan Chase
New York
|
+$44.2K |
| 4 |
SCA
Sage Capital Advisors
Sioux Falls,
South Dakota
|
+$44.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$35.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$786K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$180K |
| 3 |
VF
Virtu Financial
New York
|
-$101K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$8.84K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $68K | +$141K | +16 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $46K | +$35.4K | +4 | +57% |
|
|
3
Two Sigma Investments
New York
| $33K | +$70.7K | +8 | New |
|
|
4
JP Morgan Chase
New York
| $21K | +$44.2K | +5 | New |
|
|
SCA
5
Sage Capital Advisors
Sioux Falls,
South Dakota
| $20K | +$44.2K | +5 | New |
|
6
Tudor Investment Corp
Stamford,
Connecticut
| $18K | +$35.4K | +4 | New |
|
7
BlackRock
New York
| $15K | +$8.84K | +1 | +50% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $3K | -$8.84K | -1 | -50% |
|
9
Morgan Stanley
New York
| $1K | – | – | – |
|
|
TCWM
10
Total Clarity Wealth Management
St. Charles,
Illinois
| $1K | – | – | – |
|
|
ACM
11
AIGH Capital Management
Baltimore,
Maryland
| – | -$786K | -73 | Closed |
|
|
WVP
12
Worth Venture Partners
Fort Lee,
New Jersey
| – | -$180K | -17 | Closed |
|
|
VF
13
Virtu Financial
New York
| – | -$101K | -9 | Closed |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$1K | – | – |
|
DRMA Hedge Fund Activity: Q4 2021 in Review
8 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q4 2021, worth a combined $226K — down 81% from $1.19M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new DRMA positions and 3 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $141K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $786K sold.
- 8 institutional investors held Dermata Therapeutics (DRMA) as of Q4 2021, up from 6 in Q3 2021.
- Funds reported $226K of Dermata Therapeutics stock for Q4 2021, down 81% quarter-over-quarter.
- 5 funds opened new Dermata Therapeutics positions in Q4 2021 and 3 closed out, a net change of +2 holders.
- The largest Dermata Therapeutics buyer in Q4 2021 was Renaissance Technologies, an estimated $141K added.
- The largest Dermata Therapeutics seller in Q4 2021 was AIGH Capital Management, an estimated $786K sold.
Based on aggregated 13F filings for Q4 2021.